We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RGEN market cap is 8.91B. The company's latest EPS is USD 0.6353 and P/E is 250.26.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 172.46M | 148.64M | 151.35M | 154.07M | 161.47M |
| Operating Income | 1.78M | -7.76M | 2.03M | 1.49M | -2.13M |
| Net Income | 18.17M | -31.47M | 2.09M | 3.32M | 2.94M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 270.25M | 366.26M | 670.53M | 830.27M | 662.93M |
| Operating Income | 36.08M | 69.82M | 167.25M | 224.67M | 47.7M |
| Net Income | 21.41M | 59.93M | 128.29M | 185.96M | 35.6M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.51B | 2.83B | 2.85B | 2.86B | 2.83B |
| Total Liabilities | 525.57M | 866.34M | 878.67M | 875.56M | 813.96M |
| Total Equity | 1.99B | 1.96B | 1.97B | 1.99B | 2.02B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.4B | 1.9B | 2.36B | 2.53B | 2.83B |
| Total Liabilities | 340.35M | 373.74M | 608.29M | 620.9M | 866.34M |
| Total Equity | 1.06B | 1.53B | 1.75B | 1.91B | 1.96B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 84.85M | 113.92M | 44.71M | 86.9M | 136.22M |
| Investing | 46.63M | -123.28M | -8.36M | -15.76M | -21.62M |
| Financing | -19.17M | 248.96M | -8.97M | -14.75M | -84.35M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 67.22M | 62.63M | 119.02M | 172.08M | 113.92M |
| Investing | -205.31M | -201.39M | -221.17M | -233.24M | -123.28M |
| Financing | 484.87M | 305.92M | 961k | -13.34M | 248.96M |
| Market Cap | 8.91B |
| Price to Earnings Ratio | 250.26 |
| Price to Sales Ratio | 13.44 |
| Price to Cash Ratio | 11.86 |
| Price to Book Ratio | 4.53 |
| Dividend Yield | - |
| Shares Outstanding | 56.03M |
| Average Volume (1 week) | 1.04M |
| Average Volume (1 Month) | 651.21k |
| 52 Week Change | -18.33% |
| 52 Week High | 203.13 |
| 52 Week Low | 113.50 |
| Spread (Intraday) | 11.7 (7.22%) |
| Company Name | Repligen Corp |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.repligen.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
